Dermata Therapeutics Initiates Clinical Trial for Tome Clearing Treatment
Dermata Therapeutics has enrolled the first participant in a clinical trial for its Tome Clearing Treatment, an acne product expected to launch in the first half of 2027.
Stocks · News reference
Dermata Therapeutics Highlights Media Recognition of Tome Skincare Brand
Dermata Therapeutics announced that its Tome skincare brand has received editorial coverage in several prominent beauty and lifestyle publications following its August 2026 commercial launch.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Dermata Therapeutics, Inc. (DRMA)
Filed: 2026-10-29 AccNo: 0001493152-26-049312 Size: 204 KB Item 8.01: Other Events
Why Is Dermata Therapeutics Stock Gaining Thursday?
Dermata Therapeutics (DRMA) jumps 34% after positive clinical results for its weekly Bioneedle Tome Foundational Treatment.
Dermata Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 67.84%
Dermata Therapeutics shares are trading higher after the company reported study results showing skin appearance improvements with its Tome Foundational Treatment.
Dermata Therapeutics Announces Over 71% Of Patients Had Overall Skin Improvements At Day 29 In Its Cosmetic Clinical Trial Of Tome Foundational Treatment
Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today announced positive topline results from its recently completed cosmetic